Are you Dr. Pitukcheewanont?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 26 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
4650 W Sunset Blvd
Los Angeles, CA 90027Phone+1 323-669-4606Fax+1 323-664-0337- Is this information wrong?
Summary
- Dr. Pisit Pitukcheewanont, MD is a pediatric endocrinologist in Los Angeles, California. He is currently licensed to practice medicine in California, North Carolina, and Utah. He is affiliated with Children's Hospital Los Angeles and is an Assistant Professor at USC School of Medicine.
Education & Training
- University of TennesseeResidency, Pediatrics, 1997 - 1997
- University of TennesseeFellowship, Pediatric Endocrinology, 1994 - 1996
- Chiang Mai University Faculty of MedicineClass of 1987
Certifications & Licensure
- UT State Medical License 1900 - Present
- CA State Medical License 1998 - 2026
- NC State Medical License 1997 - 2003
Awards, Honors, & Recognition
- Super Doctor SuperDoctors.com
Clinical Trials
- The Effects of Vitamin D on Glycemic Control and Proinflammatory Markers in Adolescents With T1DM Start of enrollment: 2012 Oct 01
Publications & Presentations
PubMed
- 2 citationsBurosumab vs Phosphate/Active Vitamin D in Pediatric X-Linked Hypophosphatemia: A Subgroup Analysis by Dose Level.Erik A Imel, Francis H Glorieux, Michael P Whyte, Anthony A Portale, Craig F Munns, Ola Nilsson, Jill H Simmons, Raja Padidela, Noriyuki Namba, Hae Il Cheong, Pisit Pi...> ;The Journal of Clinical Endocrinology and Metabolism. 2023 Oct 18
- A Novel De Novo Frameshift Pathogenic Variant in the FAM111B Resulting in Progressive Osseous Heteroplasia Phenotype.Anna Ryabets-Lienhard, Panadeekarn Panjawatanan, Kyle Vogt, Jianling Ji, Senta Georgia, Pisit Pitukcheewanont> ;Calcified Tissue International. 2023 Apr 1
- 4 citationsEfficacy of Burosumab in Adults with X-linked Hypophosphatemia (XLH): A Post Hoc Subgroup Analysis of a Randomized Double-Blind Placebo-Controlled Phase 3 Study.Maria Luisa Brandi, Suzanne Jan de Beur, Karine Briot, Thomas Carpenter, Hae Il Cheong, Martine Cohen-Solal, Rachel K Crowley, Richard Eastell, Yasuo Imanishi, Erik A ...> ;Calcified Tissue International. 2022 Oct 1
- Join now to see all
Press Mentions
- Lumos Pharma, Inc. (LUMO) CEO Richard Hawkins on Q1 2022 Results - Earnings Call TranscriptMay 11th, 2022
Hospital Affiliations
- Children's Hospital Los AngelesLos Angeles, California